166 related articles for article (PubMed ID: 22574096)
1. Prostate cancer with neuroendocrine differentiation--case report.
Glück G; Mihai M; Stoica R; Andrei R; Sinescu I
J Med Life; 2012 Feb; 5(1):101-4. PubMed ID: 22574096
[TBL] [Abstract][Full Text] [Related]
2. Large-cell neuroendocrine carcinoma of prostate. Case report.
Moratalla Charcos LM; Pastor Navarro T; Cortes Vizcaino V; Osca Garcia JM; Gil Salom M
Arch Esp Urol; 2013 May; 66(4):368-71. PubMed ID: 23676541
[TBL] [Abstract][Full Text] [Related]
3. Large cell neuroendocrine carcinoma of prostate: a clinicopathologic summary of 7 cases of a rare manifestation of advanced prostate cancer.
Evans AJ; Humphrey PA; Belani J; van der Kwast TH; Srigley JR
Am J Surg Pathol; 2006 Jun; 30(6):684-93. PubMed ID: 16723845
[TBL] [Abstract][Full Text] [Related]
4. [Clinical characteristics of 13 neuroendocrine prostate cancer patients].
Zhang WH; Si TG; Yang XL; Yang B; Liu CF; Yu HP; Xing WG; Guo Z
Zhonghua Yi Xue Za Zhi; 2017 May; 97(17):1316-1319. PubMed ID: 28482433
[No Abstract] [Full Text] [Related]
5. [Neuroendocrine Differentiation of Prostate Cancer : A Case Report].
Takamizawa S; Madarame J; Kobayashi T; Kurauchi T; Maeda S; Nakajo H; Matsubara N; Kimura T; Egawa S
Hinyokika Kiyo; 2021 Oct; 67(10):465-469. PubMed ID: 34742172
[TBL] [Abstract][Full Text] [Related]
6. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
8. [A Case of de novo Neuroendocrine Prostate Cancer].
Kise H; Shiraishi T
Hinyokika Kiyo; 2021 Mar; 67(3):113-118. PubMed ID: 33957032
[TBL] [Abstract][Full Text] [Related]
9. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
10. Long-term results of a prospective, Phase II study of long-term androgen ablation, pelvic radiotherapy, brachytherapy boost, and adjuvant docetaxel in patients with high-risk prostate cancer.
Dibiase SJ; Hussain A; Kataria R; Amin P; Bassi S; Dawson N; Kwok Y
Int J Radiat Oncol Biol Phys; 2011 Nov; 81(3):732-6. PubMed ID: 21036486
[TBL] [Abstract][Full Text] [Related]
11. A first case of ductal adenocarcinoma of the prostate having characteristics of neuroendocrine phenotype with PTEN, RB1 and TP53 alterations.
Kobayashi H; Kosaka T; Nakamura K; Shojo K; Hongo H; Mikami S; Nishihara H; Oya M
BMC Med Genomics; 2021 Oct; 14(1):245. PubMed ID: 34627261
[TBL] [Abstract][Full Text] [Related]
12. Prostate carcinoma with neuroendocrine differentiation: case report and literature review.
Fernandes RC; Matsushita MM; Mauad T; Nascimento Saldiva PH
Rev Hosp Clin Fac Med Sao Paulo; 2001; 56(5):153-8. PubMed ID: 11781596
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of paneth cell-like neuroendocrine differentiation in adenocarcinoma of the prostate.
Tamas EF; Epstein JI
Am J Surg Pathol; 2006 Aug; 30(8):980-5. PubMed ID: 16861969
[TBL] [Abstract][Full Text] [Related]
14. [Neuroendocrine carcinoma of the prostate effectively treated by cisplatin and irinotecan--a case report].
Inoue S; Oka K; Araki T; Yano A; Tacho T; Fujii M; Kimoto K; Murakami M; Ohshiro Y
Gan To Kagaku Ryoho; 2007 Aug; 34(8):1323-5. PubMed ID: 17687224
[TBL] [Abstract][Full Text] [Related]
15. Preliminary results of three-dimensional conformal radiotherapy as salvage treatment for a rising prostate-specific antigen level postprostatectomy.
Wilder RB; Hsiang JY; Ji M; Earle JD; de Vere White R
Am J Clin Oncol; 2000 Apr; 23(2):176-80. PubMed ID: 10776980
[TBL] [Abstract][Full Text] [Related]
16. Asynchronous tumour quadruplicity: rectosigmoid adenocarcinoma, renal cell carcinoma, prostate adenocarcinoma and neuroendocrine small-cell lung cancer - a case report.
Adwan R; Prošvic P; Prošvicová J; Tomšová M
Rozhl Chir; 2018; 97(9):427-431. PubMed ID: 30470124
[TBL] [Abstract][Full Text] [Related]
17. Serum prostate-specific antigen as a predictor of radiographic staging studies in newly diagnosed prostate cancer.
Huncharek M; Muscat J
Cancer Invest; 1995; 13(1):31-5. PubMed ID: 7530590
[TBL] [Abstract][Full Text] [Related]
18. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995.
Kupelian P; Kuban D; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A
Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):415-9. PubMed ID: 15667961
[TBL] [Abstract][Full Text] [Related]
19. [Neuroendocrine tumor of the prostate. A case report].
Zannoud M; Ghadouane M; Kasmaoui H; Alami M; Jira H; Ouhbi Y; Albouzidi A; Abbar M
Ann Urol (Paris); 2002 Jan; 36(1):58-61. PubMed ID: 11859580
[TBL] [Abstract][Full Text] [Related]
20. Results of radiation therapy combined with neoadjuvant hormonal therapy for stage III prostate cancer: comparison of two different definitions of PSA failure.
Mitsumori M; Sasaki Y; Mizowaki T; Takayama K; Nagata Y; Hiraoka M; Negoro Y; Sasai K; Kinoshita H; Kamoto T; Ogawa O
Int J Clin Oncol; 2006 Oct; 11(5):396-402. PubMed ID: 17058138
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]